AVEVA 250MG INJ

Product Description

• Active Ingredient: Fulvestrant (250 mg per 5 ml vial/pre-filled syringe).
• Manufacturer: Zydus Cadila.
• Mechanism of Action: Fulvestrant binds to estrogen receptors in cancer cells and causes them to degrade. This action blocks the effect of estrogen, a hormone that can stimulate the growth of certain breast cancer cells, thereby slowing or stopping tumor growth.
• Usage: It is used to treat hormone receptor-positive, human epidermal growth factor receptor 2-negative (HER2-negative) advanced or metastatic breast cancer in women after menopause. It can be used alone (monotherapy) or in combination with other anti-cancer drugs like palbociclib.
• Administration: The medication is administered by a healthcare professional as a slow, deep intramuscular injection, typically into the gluteal muscle (buttocks). The typical initial dose is 500 mg (two 250 mg injections) on specific days, followed by monthly maintenance doses.
• Storage: Must be stored in a cold chain (between 2-8C).